Dark

Check out our Level2View

ANEB
ANEBULO PHARMAC INC
stock OTC

EOD

Jul 29, 2026

0.3300USD0.000%(0.0000)100

Pre-market

0.00USD-100.000%(-0.33)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 6, 2022

07:00AM EST Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference Business Wire

07:00AM EST Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations Business Wire

Jan 4, 2022

07:43AM EST Biopharmaceutical company Anebulo Pharmaceuticals, Inc. (ANEB) announced Tuesday that it has named Simon Allen as Chief Executive Officer and a member of the company's Board of Directors, effective February 1, 2022. Allen succeeds Daniel Schneeberger, MD, who has resigned as CEO and as a Director as of that same date. RTTNews

07:32AM EST Anebulo Pharma Names Simon Allen As CEO, Effective Feb 1 RTTNews

07:19AM EST Anebulo Pharmaceuticals Names Simon Allen As CEO And Director Benzinga

07:00AM EST Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director Business Wire

Jan 3, 2022

07:05AM EST Anebulo Pharma Begins Phase 2 Clinical Study Of ANEB-001 For Acute Cannabinoid Intoxication RTTNews

07:04AM EST Anebulo Pharma Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication Benzinga

07:00AM EST Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication Business Wire

Nov 12, 2021

08:23AM EST Anebulo Pharmaceuticals Q1 Net Loss $1.5 Mln Vs. Net Loss $256,379 Last Year RTTNews

08:00AM EST Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update Business Wire

Oct 13, 2021

01:38PM EDT Anebulo Pharmaceuticals Announces Issuance Of US Patent Covering Use Of ANEB-001 For Treatment Of Acute Cannabinoid Overdose Benzinga

08:00AM EDT Anebulo Pharmaceuticals Announces Issuance of U.S. Patent Covering Use of ANEB-001 for the Treatment of Acute Cannabinoid Overdose Business Wire

Oct 12, 2021

09:00AM EDT Overdose Unknown: How Anebulo Pharmaceuticals Is Working to Solve a Growing Marijuana Overdose Problem Benzinga

Oct 5, 2021

09:34AM EDT The Risks of Cannabis Over-Consumption Benzinga

08:00AM EDT Anebulo Pharmaceuticals to Participate in the Benzinga Cannabis Capital Conference in New York City Business Wire

Sep 27, 2021

07:41AM EDT The Unintended Consequences of Ever-Increasing Marijuana Potency Benzinga

Sep 23, 2021

10:49AM EDT CBD-Focused Anebulo Pharma Posts Q4 & Full Year 2021 Earnings, Launching Phase 2 Cannabis Overdose Clinical Trials Benzinga

Sep 22, 2021

04:07PM EDT Anebulo Pharmaceuticals Q4 EPS $(1.59) Benzinga

04:07PM EDT Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Business Update Business Wire

Sep 20, 2021

08:13AM EDT Cannabis Edibles are Leading to More Negative Outcomes in Cannabis Users Benzinga

Sep 13, 2021

08:12AM EDT Anebulo Pharma Announces Completion Of Manufacturing Of ANEB-001 Capsules For Upcoming Phase 2 Clinical Trial RTTNews

08:01AM EDT CB1 Antagonists as a Solution to the Complicated Problems of Cannabis Over-intoxication Benzinga

08:00AM EDT Anebulo Pharmaceuticals Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical Trial Business Wire

Sep 7, 2021

08:00AM EDT Anebulo Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Business Wire

07:04AM EDT Anebulo is Developing an Antidote to Cannabis Intoxication Benzinga

Aug 30, 2021

07:32AM EDT The Treatment of Cannabis Toxicity Benzinga

Aug 23, 2021

12:48PM EDT Cannabis Legalization is Driving an Increase in Related ER Visits Benzinga

Aug 16, 2021

08:39AM EDT Alcohol, Cannabis and Synergistic Risk Benzinga

Aug 13, 2021

03:09PM EDT Cannabis Movers & Shakers: Creo, Harvest Health & Recreation, Glass House, Flora Growth, Anebulo, Cannformatics, Republic Brands Benzinga

Aug 12, 2021

08:16AM EDT Anebulo Pharmaceuticals Announces Formation Of Scientific Advisory Board Benzinga

08:00AM EDT Anebulo Pharmaceuticals Announces Formation of Scientific Advisory Board, Names First Two Members Business Wire

Aug 10, 2021

03:38PM EDT Cannabis Over-Intoxication Results in Millions of Visits to the ER per Year Benzinga

Aug 6, 2021

09:56AM EDT The Underappreciated Risk Of Pediatric Cannabis Overdose Benzinga

Jul 26, 2021

08:41PM EDT The Danger of Synthetic Cannabinoids Benzinga

Jul 12, 2021

08:22AM EDT The Dark Side of Cannabis Legalization and one Biotech Company's Solution Benzinga

Jun 22, 2021

10:27AM EDT Cannabinoid-Focused Anebulo Pharma Posts Q3 Earnings, On Schedule To Start Cannabis Overdose Clinical Trials Benzinga

Jun 21, 2021

04:16PM EDT Anebulo Pharmaceuticals Q3 2021 Total Expenses ~$552K; EPS $(0.69) vs $(0.74) In Same Qtr. Last Year Benzinga

04:15PM EDT CORRECTION: Anebulo Pharma Q3 EPS $(0.69) vs $(0.74) In Same Qtr. Last Year Benzinga

04:11PM EDT Anebulo Pharmaceuticals Q3 2021 Total Expenses ~$552K; EPS $(0.04) Benzinga

04:05PM EDT Anebulo Pharmaceuticals Reports Recent Business Highlights and Announces Third Quarter Fiscal Year 2021 Financial Results Business Wire

May 25, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021 Benzinga

07:25AM EDT Benchmark Initiates Coverage On Anebulo Pharmaceuticals with Buy Rating, Announces Price Target of $15 Benzinga

May 21, 2021

07:26AM EDT The Daily Biotech Pulse: Moderna's Vaccine Authorized In Japan, Neovasc's Adverse Ruling In Germany, Metacrine Rallies On Insider Buying Benzinga

May 7, 2021

10:20AM EDT Anebulo Pharmaceuticals Shares Open For Trade At $7.38; IPO Priced At $7/Share Benzinga

09:31AM EDT IPOs For Friday, May 7: Bowman Consulting Group, Priced At $14/Share; Anebulo Pharmaceuticals, Priced At $7/Share; Data Knights Acquisition Corp., Priced At $10/Unit; Talaris Therapeutics, Priced At $17/Share Benzinga

07:59AM EDT Anebulo Pharmaceuticals Shares Will Open For Quote At 9:50 a.m. EDT, Expected To Open For Trade After 10 a.m. EDT; IPO Priced At $7/Share Benzinga

07:59AM EDT CORRECTION: Anebulo Pharmaceuticals Shares Will Open For Quote At 9:50 a.m. EDT, Expected To Open For Trade After 10 a.m. EDT; IPO Priced At $7/Share Benzinga

07:56AM EDT Anebulo Pharmaceuticals Shares Will Open For Quote At 10:35 a.m. EDT, Expected To Open For Trade After 10:45 a.m. EDT; IPO Priced At $7/Share Benzinga

07:21AM EDT Anebulo Pharmaceuticals Late Thursday Priced Its IPO of 3M Shares At $7/Share Benzinga

May 6, 2021

08:00PM EDT Anebulo Pharmaceuticals Announces Pricing of Initial Public Offering Business Wire

Share